David Henry, MD, of Pennsylvania Hospital, discusses the exciting developments in multiple myeloma treatment, including the three new drugs approved for the disease in November 2015.
Simon Rule, MD, of Derriford Hospital, discusses results from an international, multicenter study in patients with previously treated mantle cell lymphoma (Abstract 469).
Margaret O'Donnell, MD, of the City of Hope National Medical Center, summarizes a session on this vital topic (Session 613).
James Foran, MD, of the Mayo Clinic Cancer Center, discusses two key studies on clofarabine: as a single agent for induction and postremission therapy in newly diagnosed AML, and as the basis for consolidation in nonfavorable AML (Abstracts 217 and 218).
Jonathon B. Cohen, MD, of the Winship Cancer Institute, discusses a study that used the National Cancer Data Base to study the impact on overall survival of deferring treatment in patients with newly diagnosed mantle cell lymphoma (Abstract 2717).
S. Vincent Rajkumar, MD, of the Mayo Clinic, summarizes his education session on the evolving diagnostic criteria for myeloma, which focused on smoldering disease and when it becomes an “open flame.”
